Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy
Objectives: To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to evaluate the potential benefits of a new prophylaxi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2025-01-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/3182 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832578334754603008 |
|---|---|
| author | Andrea Marcellusi Chiara Bini Barbara Muzii Samira Soudani Alexia Kieffer Matthieu Beuvelet Elena Bozzola Fabio Midulla Eugenio Baraldi Paolo Bonanni Sara Boccalini Luigi Orfeo |
| author_facet | Andrea Marcellusi Chiara Bini Barbara Muzii Samira Soudani Alexia Kieffer Matthieu Beuvelet Elena Bozzola Fabio Midulla Eugenio Baraldi Paolo Bonanni Sara Boccalini Luigi Orfeo |
| author_sort | Andrea Marcellusi |
| collection | DOAJ |
| description | Objectives: To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to evaluate the potential benefits of a new prophylaxis strategy targeting all infants with nirsevimab.
Methods: A static decision analytic model previously used in the US was adapted to evaluate the RSV-related health and cost outcomes associated with nirsevimab versus standard of care (SoC) for the prevention of RSV medically attended lower respiratory tract infections (RSV-MA-LRTIs). Monthly probabilities of RSV infections, health events, mortality, and complications associated with RSV infections were obtained from the literature. Costs associated with each event were obtained using the available literature and through real-world data analysis of National Hospital Discharge Records.
Results: For one RSV season, in the current SoC, the model estimated 216,100 RSV-MA-LRTIs, 15,121 associated complications, and 16 RSV-deaths–corresponding to an economic burden of approximately €50.5 million related to RSV-MA-LRTIs management, €10.9 million associated with potential complications due to RSV and €3 million in lost productivity due to RSV-deaths. Nirsevimab is expected to prevent 100,208 RSV-MA-LRTIs, 6,969 complications, and 6 deaths due to RSV infections, corresponding to an economic saving of about €23.3, €5, and €1.2 million, respectively.
Conclusion: Nirsevimab is a new prophylaxis strategy that helps to protect all infants against RSV disease and could substantially reduce the clinical and economic burden of RSV in Italy in infants experiencing their first RSV season.
|
| format | Article |
| id | doaj-art-a6a096562769446d8def13c64a2361a5 |
| institution | Kabale University |
| issn | 2284-2403 2283-5733 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj-art-a6a096562769446d8def13c64a2361a52025-01-30T14:04:15ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332025-01-0112110.33393/grhta.2025.3182Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in ItalyAndrea Marcellusi0Chiara Bini1Barbara Muzii2Samira Soudani3Alexia Kieffer4Matthieu Beuvelet5Elena Bozzola6Fabio Midulla7Eugenio Baraldi8Paolo Bonanni9Sara Boccalini10Luigi Orfeo11Centre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome “Tor Vergata”, Rome - ItalyCentre for Economics and International Studies-Economic Evaluation and Health Technology Assessment, Faculty of Economics, University of Rome “Tor Vergata”, Rome - ItalySanofi, Rome - ItalySanofi, Lyon - FranceSanofi, Lyon - FranceSanofi, Lyon - FranceIRCCS Bambino Gesù Children Hospital, Rome - ItalyDepartment of Maternal Science, Paediatric Emergency Service, Sapienza University of Rome, Rome - ItalyDepartment of Women’s and Children’s Health, University of Padova, Institute of Pediatric Research “Città della Speranza”, Padova - ItalyDepartment of Health Sciences, University of Florence, Florence - ItalyDepartment of Health Sciences, University of Florence, Florence - ItalyNeonatal Intensive Care Unit, “Isola Tiberina Hospital - Gemelli Isola”, Rome - ItalyObjectives: To describe the seasonal respiratory syncytial virus (RSV) burden in Italy considering the current prophylaxis strategy with palivizumab recommended only for high-risk infants (representing only 4.4% of an estimated birth cohort) and to evaluate the potential benefits of a new prophylaxis strategy targeting all infants with nirsevimab. Methods: A static decision analytic model previously used in the US was adapted to evaluate the RSV-related health and cost outcomes associated with nirsevimab versus standard of care (SoC) for the prevention of RSV medically attended lower respiratory tract infections (RSV-MA-LRTIs). Monthly probabilities of RSV infections, health events, mortality, and complications associated with RSV infections were obtained from the literature. Costs associated with each event were obtained using the available literature and through real-world data analysis of National Hospital Discharge Records. Results: For one RSV season, in the current SoC, the model estimated 216,100 RSV-MA-LRTIs, 15,121 associated complications, and 16 RSV-deaths–corresponding to an economic burden of approximately €50.5 million related to RSV-MA-LRTIs management, €10.9 million associated with potential complications due to RSV and €3 million in lost productivity due to RSV-deaths. Nirsevimab is expected to prevent 100,208 RSV-MA-LRTIs, 6,969 complications, and 6 deaths due to RSV infections, corresponding to an economic saving of about €23.3, €5, and €1.2 million, respectively. Conclusion: Nirsevimab is a new prophylaxis strategy that helps to protect all infants against RSV disease and could substantially reduce the clinical and economic burden of RSV in Italy in infants experiencing their first RSV season. https://journals.aboutscience.eu/index.php/grhta/article/view/3182Cost of IllnessPrevention strategyRespiratory syncytial virusUniversal immunization |
| spellingShingle | Andrea Marcellusi Chiara Bini Barbara Muzii Samira Soudani Alexia Kieffer Matthieu Beuvelet Elena Bozzola Fabio Midulla Eugenio Baraldi Paolo Bonanni Sara Boccalini Luigi Orfeo Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy Global & Regional Health Technology Assessment Cost of Illness Prevention strategy Respiratory syncytial virus Universal immunization |
| title | Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy |
| title_full | Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy |
| title_fullStr | Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy |
| title_full_unstemmed | Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy |
| title_short | Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy |
| title_sort | economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in italy |
| topic | Cost of Illness Prevention strategy Respiratory syncytial virus Universal immunization |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/3182 |
| work_keys_str_mv | AT andreamarcellusi economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT chiarabini economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT barbaramuzii economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT samirasoudani economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT alexiakieffer economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT matthieubeuvelet economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT elenabozzola economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT fabiomidulla economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT eugeniobaraldi economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT paolobonanni economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT saraboccalini economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly AT luigiorfeo economicandclinicalburdenassociatedwithrespiratorysyncytialvirusandimpactofuniversalimmunizationwithnirsevimabinitaly |